Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

Area of Science:

• Hematology
• Immunology
• Rheumatology

Background:

• Diffuse cutaneous systemic sclerosis (scleroderma) often leads to poor outcomes despite existing treatments.
• Autologous hematopoietic stem-cell transplantation (HSCT) is being explored as a potential therapy.

Purpose of the Study:

• To compare the efficacy and safety of myeloablative autologous HSCT versus monthly cyclophosphamide infusions in severe scleroderma patients.

Main Methods:

• Randomized trial comparing myeloablative autologous HSCT (36 participants) with cyclophosphamide (39 participants) in adults aged 18-69 with severe scleroderma.
• Primary endpoint assessed at 54 months using a global rank composite score including survival, event-free survival, forced vital capacity, and skin/disability scores.

Main Results:

• Transplantation demonstrated superiority in the global rank composite score (P=0.01) and event-free survival at 54 months (79% vs. 50%, P=0.02).
• At 72 months, transplantation showed improved event-free (74% vs. 47%) and overall survival (86% vs. 51%) (P=0.03 and P=0.02, respectively).
• Fewer transplant recipients required disease-modifying antirheumatic drugs (DMARDs) (9% vs. 44%, P=0.001), though treatment-related mortality was 6% at 72 months.

Conclusions:

• Myeloablative autologous HSCT provides sustained long-term benefits for scleroderma patients, including enhanced survival.
• The observed toxicity and treatment-related mortality were within expected ranges and lower than some previous reports.
• This approach represents a viable option for severe scleroderma, warranting further investigation into risk-benefit profiles.